NASDAQ: MASS908 Devices Inc Stock
$7.52-1.11 (-12.86%)
Updated Mar 17, 2023
MASS Price
$7.52
Fair Value Price
$14.92
Market Cap
$240.99M
52 Week Low
$6.87
52 Week High
$26.00
P/E
-7.03x
P/B
1.26x
P/S
5.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$46.85M
Earnings
-$33.56M
Gross Margin
55.5%
Operating Margin
-71.36%
Profit Margin
-71.6%
Debt to Equity
0.27
Operating Cash Flow
-$21M
Beta
2.05
Next Earnings
May 8, 2023
Ex-Dividend
N/A
Next Dividend
N/A
MASS Overview
908 Devices Incorporated provides purpose-built handheld and desktop mass spectrometry devices used in life sciences research, bioprocessing, industrial biotech, and forensics. Offerings include MX908, a handheld, battery-powered device designed for the rapid analysis of gas, liquid, and solid materials of unknown identity, Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses, and ZipChip, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. 908 Devices was incorporated in 2012 and is headquartered in Boston, MA.
Zen Score
–
Industry Average (31)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MASS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MASS ($7.52) is undervalued by 49.61% relative to our estimate of its Fair Value price of $14.92 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MASS ($7.52) is significantly undervalued by 49.61% relative to our estimate of its Fair Value price of $14.92 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
MASS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MASS due diligence checks available for Premium users.
Be the first to know about important MASS news, forecast changes, insider trades & much more!
MASS News
Valuation
MASS fair value
Fair Value of MASS stock based on Discounted Cash Flow (DCF)
Price
$7.52
Fair Value
$14.92
Undervalued by
49.61%
MASS ($7.52) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MASS ($7.52) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MASS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MASS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.03x
Industry
93.94x
Market
21.81x
MASS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.26x
Industry
3.75x
MASS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MASS's financial health
Profit margin
Revenue
$11.6M
Net Income
-$9.8M
Profit Margin
-84.1%
MASS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MASS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$242.6M
Liabilities
$52.0M
Debt to equity
0.27
MASS's short-term assets ($215.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MASS's short-term assets ($215.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MASS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.1M
Investing
-$612.0k
Financing
$411.0k
MASS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MASS vs Medical Device Stocks
908 Devices Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.